BRCA1 and neoplasm: One of the two chemo-naive PDX with homozygous BRCA1 promoter methylation (#62) responded to 300 mg kg−1 rucaparib, with tumor regressions observed in two of seven mice (median TTH 71 days vs. vehicle 18 days, p < 0.001, log-rank test, n = 7, 11) (Table 1, Fig. 3e).